Health Populi
APRIL 26, 2022
Compared with a year ago, more patients and their advocates are seeking quality therapies, innovation, engagement, and integrity from pharmaceutical companies, based on research published today from PatientView. Expect patient access programs to need more hands, and more creative approaches, on deck in and beyond 2022.
Society for Participatory Medicine
JANUARY 27, 2022
Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and life sciences firms, and insurance companies serve patients as end users. And I propose a toast: “To stop talking about involving patients and actually do it in 2022. Connect with her at [link]. Did you enjoy this post?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Health Populi
MAY 20, 2021
health citizens’ memories will last into 2022 with respect to cross-party desire for the U.S. to approve Medicare’s negotiation of drug prices with pharmaceutical companies]. The one segment which has stayed relatively even from 2018 has been biotech, 55% that year and 55% again in 2021. On these factors, the U.S.
Society for Participatory Medicine
FEBRUARY 1, 2023
Flash back to my article for the Society for Participatory Medicine last year: Let’s Save the Date and Make Patient Engagement Official in 2022. After all of this time and energy expended, it’s only right that patients would be witness to accountability of pharma/biotech to incorporate our collective voice.
Digital Health Global
MARCH 1, 2023
With over 20 years of experience in pharmaceutical, medtech, digital health, biotech and diagnosis, Julie’s leadership approach focuses on inspiring teams to deliver sustainable growth in challenging markets and healthcare environments. Since 2022, Julie has served as Executive Chair of the Board of Directors of Mundipharma China.
Health Populi
MAY 4, 2023
First, we look at the macro picture on health services utilization comparing the end of 2022 with pre-COVID-19 levels. The second graph portrays the same data in greater granularity, illustrating the variability of the four service areas over time comparing Q2 2020 with Q4 2022.
Lloyd Price
SEPTEMBER 16, 2023
Exec Summary: Investment into the Scottish healthtech market in 2022 reached a record high of £705 million, surpassing the previous record of £626 million set in 2021. The company raised $10m in 2022. This represents a year-on-year increase of 12%. Resolution Therapeutics is a spin-out of the University of Edinburgh.
Expert insights. Personalized for you.
389 
Let's personalize your content